[vc_row][vc_column][vc_column_text]Concerns have been accumulating on the widespread use of all the current classes of antidepressants.

This is reflected in the recently published North American based treatment guidelines (Grunze et al. 2002; Hirschfeld et al., 2002); including those of the APA (Sachs, et al., 2000).  These recommendations have voiced considerable limitations and a conservative attitude to their use, recommending use be restricted to severe bipolar depressions (Goodwin and Jamison, 1990; Murray and Lopez, 1996; Bostwick and Pankratz, 2000).  The recommendations go on to suggest that if antidepressants are used they should be withdrawn as early as possible; thus we are now seeing a shift away from both the use of the current classes of antidepressants and recommendations for their long-term use since they are associated with the following problems.

The risk for induced mania.

There is now established a considerable risk of antidepressant induced manic switching and/or rapid cycling.  This is seen in both short term and long term exposures.  For example with selective reuptake inhibitors (SRIs) clinical samples demonstrate length of switch that are not minimal, that is 15 to 27%.  The authors of a number of review articles on this topic suggest that the real rates are around 40% for tricyclic antidepressants and 20% with new SRI antidepressants.  Substance abuse has been shown to be a major predictor of antidepressant-induced mania.

The risk of suicide in bipolar depressed patients.

This risk is in and of itself a significant issue of concern.  An analysis of SRIs and other novel antidepressants submitted to the FDA totaling nearly 20 thousand cases showed that there was no significant difference in completed or attempted suicides between patients on antidepressants and placebo treated groups.  Simply stated, it appears that antidepressants as a group have not been shown to adequately reduce suicide rates.  However, the data on lithium is in contrast to this with a very well established finding of its prophylactic effects against suicidality in a variety of diagnostic categories.

Antidepressant efficiency in treating bipolar depression.

Prophylactic studies with antidepressants are not robust in the treatment of depressive episodes in bipolar disorders.  Again, in contrast, the evidence of efficiency in treating bipolar depression with mood stabilizers is much higher (e.g., lithium and lamotrogine).[/vc_column_text][/vc_column][/vc_row]